Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB).
about
Biology of adeno-associated viral vectors in the central nervous systemAdeno-associated Virus as a Mammalian DNA VectorCurrent prospects and challenges for epilepsy gene therapyAdeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success--a personal perspectiveChanging channels in pain and epilepsy: Exploiting ion channel gene therapy for disorders of neuronal hyperexcitabilityE Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV EvolutionDevelopment of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene TransferTargeted delivery of self-complementary adeno-associated virus serotype 9 to the brain, using magnetic resonance imaging-guided focused ultrasoundAdenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy.Combinatorial approaches for the identification of brain drug delivery targets.Development of a Novel AAV Gene Therapy Cassette with Improved Safety Features and Efficacy in a Mouse Model of Rett SyndromeAAV's anatomy: roadmap for optimizing vectors for translational successSystemic gene delivery to the central nervous system using Adeno-associated virus.Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates.Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo.Inhibitory RNA in epilepsy: research tools and therapeutic perspectivesDirected evolution of novel adeno-associated viruses for therapeutic gene delivery.Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disordersPseudotyped AAV vector-mediated gene transfer in a human fetal trachea xenograft model: implications for in utero gene therapy for cystic fibrosis.Gene therapy in epilepsy-is it time for clinical trials?Beyond the hammer and the scalpel: selective circuit control for the epilepsiesSynthetic virology: engineering viruses for gene deliveryRETRACTED: Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapyMicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expressionAdenosine kinase as a target for therapeutic antisense strategies in epilepsy.Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primatesOptimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors.Gene therapy for the nervous system: challenges and new strategies.Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques.Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids.The AAV vector toolkit: poised at the clinical crossroadsClinical applications involving CNS gene transfer.Methods for gene transfer to the central nervous system.Pulmonary Targeting of Adeno-associated Viral Vectors by Next-generation Sequencing-guided Screening of Random Capsid Displayed Peptide Libraries.In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene TherapyA brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases.Identification and Validation of Small Molecules That Enhance Recombinant Adeno-associated Virus Transduction following High-Throughput Screens.Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease.Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice.A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype
P2860
Q21129328-6B5C0269-0D4F-4A7D-B4E8-5ECD35AD9281Q26782605-8E06C177-D5A8-47B7-89A2-F58F327C664CQ27002627-528E9E1B-6F8B-4CB0-8D68-DB496A60978BQ27012320-5F6B8520-783D-4EEC-B804-ADC2100EFA13Q28081164-52EC631F-1BED-4974-8995-F5911C9619B0Q28083324-C0D245D2-F6A1-4EE5-B70A-94C99C4E7C65Q30152887-5175144C-734E-443E-B510-29DE5B239031Q30447740-22A997E7-C40F-4745-A834-FCAAE8BC54B2Q30605561-BF0A13FB-5CF0-4D5F-86EB-C9066DDF451EQ31119779-F3D0415A-DA5B-4707-BFFC-B0766E8D2995Q33652467-C824A2A3-F527-4C17-8580-AE630E39A690Q33659389-C9BDC278-636D-4178-ABA4-CA96B4DD5827Q33695674-82C07E7D-EF97-4DA9-BA8E-3FB125FC47EEQ33805560-41A9300F-5C97-43B8-9B51-6D643BC8CAC4Q33924645-6C6C8831-6BAE-4E77-B9F0-BA32B41E194AQ34126428-02764B88-8BDC-4C5B-B20F-17AC1412F5FAQ34188892-4530DCC1-F06C-4954-B715-7FAD1E4BF2A7Q34205620-E6CE2B95-A501-4E91-8B8C-0CEB0C5072C6Q34399258-6A45C23A-0F0B-4735-83BA-1E8A84B55C83Q34410588-F5653D0C-EA9B-40B7-BA31-B284376FD88CQ34464281-ABC8CF8A-72B7-435C-82E4-E241CBAE426EQ34487264-09FB6C92-E7ED-4DAC-A1E7-E6ABB5868EACQ34621544-3F7A0651-8861-4D1E-A1EB-7F20065DED4FQ34621747-8B20B5B3-B731-470D-97C2-D21752F44460Q34788009-2B6E5BD5-04A1-4859-A7E0-4594CE1D1528Q35086714-430C0496-A618-4D97-89C5-F38024F43628Q35226125-A9E8134E-CA58-4C9E-AAC7-7861F0CB815BQ35340196-287FA008-7122-4D40-8050-57EC8810BCDAQ35746222-3C8430E8-353F-46E7-95D9-A7E10C275F74Q35853990-6E42FBF1-B89A-4AC6-94FD-AA73C9415DCFQ35876224-1F10DEC6-27B9-4625-88E2-824F28D1A1E0Q35899850-FC7A4731-8E14-4828-88B0-0EAB5B6E283DQ35902332-5278F683-370D-4696-9948-B151F0E749A8Q35971198-8C2D5E1B-E009-463F-AD70-C05AC53D44F3Q35999976-7E00F925-0D73-4F78-9873-32F321C54C93Q36006011-3C68AD6D-AD46-4F67-9F45-A1BC3A2C7771Q36009041-EDBC04D4-FE0F-47D2-A577-B36B5F0105F2Q36401067-5E6C106D-40EF-4468-8D4F-8D9CCC41B4DDQ36507871-3047C0CB-59E2-4BC3-B2E9-86083CEE4CA6Q36715338-179ACF1F-4784-42A5-85B4-7A2B762F30BB
P2860
Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB).
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Directed evolution of a novel ...... sed blood-brain barrier (BBB).
@ast
Directed evolution of a novel ...... sed blood-brain barrier (BBB).
@en
Directed evolution of a novel adeno-associated virus
@nl
type
label
Directed evolution of a novel ...... sed blood-brain barrier (BBB).
@ast
Directed evolution of a novel ...... sed blood-brain barrier (BBB).
@en
Directed evolution of a novel adeno-associated virus
@nl
prefLabel
Directed evolution of a novel ...... sed blood-brain barrier (BBB).
@ast
Directed evolution of a novel ...... sed blood-brain barrier (BBB).
@en
Directed evolution of a novel adeno-associated virus
@nl
P2093
P2860
P921
P356
P1433
P1476
Directed evolution of a novel ...... sed blood-brain barrier (BBB).
@en
P2093
Bonita L Blake
Hugh E Criswell
R Jude Samulski
Sarah C Nicolson
Steven J Gray
Thomas J McCown
P2860
P304
P356
10.1038/MT.2009.292
P577
2009-12-29T00:00:00Z